Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.48), Zacks reports. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The business had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.18 million.
Xenetic Biosciences Stock Performance
Shares of NASDAQ:XBIO opened at $3.56 on Wednesday. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.20. The company has a market capitalization of $5.49 million, a P/E ratio of -1.34 and a beta of 2.17. The company has a 50-day simple moving average of $4.01 and a 200 day simple moving average of $4.00.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.
About Xenetic Biosciences
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Read More
- Five stocks we like better than Xenetic Biosciences
- What is the NASDAQ Stock Exchange?
- 3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow Margins
- What is a Special Dividend?
- Retail Sales Data Signals a Surge: The E-Commerce Stock Picks
- How Investors Can Find the Best Cheap Dividend Stocks
- Qualcomm’s Low PE Ratio Makes It A Seriously Attractive Stock
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
